Advisory committees comprised of content experts, practitioners, and patient advocates from across Texas assist CPRIT and its Oversight Committee by focusing upon particular issues critical to CPRIT’s efforts. While some CPRIT advisory committees are created by statute, the Oversight Committee may create additional committees of experts to provide advice on specific cancer-related topics. With the input of its advisory committees, the Oversight Committee is better-equipped to make the informed decisions about CPRIT’s programs and policies.
Looking for CPRIT’s peer review committees? Click here
The University Advisory Committee (UAC) advises the Oversight Committee about the role of higher education in cancer research. The nine members of the UAC include representatives of all of Texas’ public university systems and private research universities.
The Advisory Committee on Childhood Cancers (ACCC) advises the Oversight Committee on issues surrounding childhood cancer. The Oversight Committee is responsible for appointing members to the committee. The ACCC collects current information regarding innovative research on the prevention, control and cure of childhood cancers, and current information regarding treatment programs designed to prevent and control cancer.
The Scientific and Prevention Advisory Council (SPAC) assimilates current information regarding innovative research on the prevention, control, and cure of cancer, and current information regarding treatment programs designed to prevent and control cancer. SPAC committee members, appointed by the Oversight Committee, bring a variety of experiences and perspectives related to cancer care, prevention, research and commercialization opportunities. At least twice each year, the Council informs the Oversight Committee about:
- Cancer research, including the state of cancer research; promising areas of research—basic science, translational science, clinical trials, and health care delivery; and other issues to advance the goals and missions of the Institute: and
- Cancer prevention programs, including the state of cancer prevention programs; the most innovative approaches to cancer prevention programs; the most effective approaches to delivering cancer prevention programs; the most promising cancer prevention program opportunities—researching effective programs, design and initial implementation of programs, and execution of programs; and other issues to advance the goals and mission of the Institute.
The Commercialization Advisory Committee (CAC) provides expertise to the Oversight Committee on the growing gap between translational discovery and later stage clinical development of new oncology drugs in Texas. Primarily, it is making recommendations on the breadth of life science expertise needed in Texas to advance the state’s ability to improve cancer patient outcomes from promising scientific discoveries.